Crescent Biopharma (CBIO) Shares Outstanding (Weighted Average) (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $27.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $27.6 million, down 57.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.6 million (down 57.27% YoY), and the FY2025 annual result was $27.6 million, down 57.26% from the prior year.
• Shares Outstanding (Weighted Average) held at $27.6 million in Q1 2026 per CBIO's latest filing, from $27.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $64.5 million in Q1 2025 and troughed at $13.9 million in Q2 2025.
• A 5-year average of $50.8 million and a median of $60.4 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) gained 20.58% in 2023, then sank 78.46% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $52.5 million in 2022, then climbed by 20.58% to $63.3 million in 2023, then climbed by 1.79% to $64.5 million in 2024, then sank by 57.26% to $27.6 million in 2025, then increased by 0.06% to $27.6 million in 2026.
• Business Quant data shows CBIO's Shares Outstanding (Weighted Average) at $27.6 million in Q1 2026, $27.6 million in Q4 2025, and $13.9 million in Q3 2025.